Skip to main content

EU research regulation

EU Issuer-Sponsored Research Rules

Under MiFID II, “issuer-sponsored research” is a regulated label. Issuers planning EU distribution need to address the contract, editorial safeguards, and release format early. A disclosure added just before publication cannot establish that the research was produced under the required controls.

On this page

The directive and the final code

Directive (EU) 2024/2811 amended Article 24 of MiFID II through the EU Listing Act. Article 4 set June 5, 2026 as the deadline for Member States to transpose the directive and June 6, 2026 as the date to apply those national provisions. The Commission’s final Delegated Regulation (EU) 2026/1092 was published on September 4, 2026 and entered into force on September 7, 2026. The regulation applies directly in EU Member States and contains the code in its annex.

Article 24(3a) requires covered research to be fair, clear, and not misleading and identifiable as research when the applicable organizational conditions are met. Under paragraphs 3b and 3e, investment firms within scope can distribute issuer-paid research to clients or prospective clients under the issuer-sponsored label only when it complies with the code. The directive requires issuer-paid material that falls within the framework and fails the code to carry the marketing communication label.

The final code should be read alongside the directive and other applicable rules. Article 20 of the Market Abuse Regulation addresses objective presentation and conflicts for investment recommendations. Delegated Regulation (EU) 2016/958 sets out related technical requirements. A valuation opinion can require a recommendation analysis even when the publication format omits a conventional rating.

Contract duration, payment, and editorial control

The final regulation governs the structure of engagements intended to qualify under the code. Clause 5 requires an initial term of at least two years and renewals of at least one year. A contract may allow early termination on objective grounds, such as delisting, repeated failure to pay, or systematic delays in delivery. Issuer dissatisfaction with the analysis or recommendation cannot be grounds for early termination.

The issuer must pay at least 50% of annual remuneration as soon as possible after signature and on each contract anniversary. Remuneration arrangements must safeguard the analyst’s objectivity and independence and exclude variable elements linked directly or indirectly to research content. The fee schedule and termination terms therefore warrant review alongside the scope of work.

Clauses 2 and 3 address conflicts and organizational safeguards. The provider maintains a conflicts policy and register, reviews the policy at least annually, and investigates potential breaches, with prompt notification to the issuer. The code sets controls for analyst trading and information barriers, prohibits promises of favorable coverage, and requires safeguards around analyst participation in solicitation or contract negotiations. It restricts prerelease review by issuers and other relevant persons outside the analyst team when a draft contains a recommendation or target price, with an exception for checking compliance with the firm’s legal obligations. Providers must ensure third-party analysts comply with the relevant conflicts and objectivity provisions.

The code also requires parity in analyst qualifications, resources, and content type between sponsored and non-sponsored research. It bars issuers and their representatives from trying to influence the content. The analyst is responsible for media relations and social content for the research and must remind journalists of the sponsorship contract.

What readers must see and when they can access it

Clause 4 requires the issuer-sponsored research label and a prominent indication of compliance with the code on the front and any cover page. The label also appears on each page, including in electronic communications. The concise disclosure summary includes whether funding is full or partial, the access classification, where the conflicts policy is available, and the specified revenue and relationship disclosures.

The revenue disclosures consider issuer payments, other issuer-related revenue, and revenue from the sponsored research against the threshold of more than 5% of the provider’s consolidated gross revenues in the previous financial year. A separate disclosure is required where applicable for the provider or a third-party analyst involved in the research. The summary also describes the nature of applicable client or contractual relationships with the issuer over the preceding 12 months, including liquidity arrangements. The detail in Clause 4 is important when the provider has several forms of issuer-related revenue.

Under Clause 6, fully issuer-paid research must be accessible to the public free of charge. For this purpose the code treats research as fully paid by the issuer when the provider is contractually prohibited from offering it for payment to anyone else. Clause 4 provides access labels for work that is public or reserved for contributing investors indefinitely or until a specified date. For a partly funded mandate, confirm the applicable classification and how access will be administered.

During the contract, Clause 7 calls for best efforts to publish a timely update after important public information likely to have a significant impact on the covered instruments. It also requires relabeling as a marketing communication upon becoming aware that the updated research no longer meets the code. Clauses 8 and 9 cover information sharing with investment firms and recordkeeping. Providers keep the agreement and payment records, source material, published research, and conflicts documentation. Article 24(3d) also provides for voluntary submission by the issuer to the relevant collection body under the European Single Access Point framework with metadata indicating code compliance.

Start with the investment firm and the distribution route

Identify the payer, the legal entity preparing the report, each distributor, and the proposed clients or prospective clients. A non-EU issuer or publisher can be involved where a MiFID investment firm distributes the research to its clients. An EU listing alone does not resolve the analysis. Check the relevant national implementing provisions, the firm’s role, and local rules for each route. The regulation’s EEA relevance designation also warrants a check of incorporation and local application outside the EU where relevant.

Article 2 requires investment firms to obtain the information needed to assess compliance with the code. They may consider an independent third party’s assessment or take into account the regulated status of a provider that is itself an investment firm subject to the regulation. Responsibility for the firm’s obligations remains with the investment firm. Where it has insufficient information, it cannot distribute the research to clients or prospective clients under the issuer-sponsored label.

Consider a Canadian company that hires a UK research provider and plans to distribute the report through an EU investment firm. The firm will need to assess whether the agreement, review process, and publication qualify for the EU label before using it in client distribution. The issuer and provider should allocate the responsibility for documentation and distribution at the outset, since the provider may also be preparing a version for publication in another market.

For a proposed mandate, the issuer and provider should agree who supplies the contractual and conflicts documentation and who applies the label in each format. The relevant investment firm and compliance counsel can confirm what applies to the intended audience and route. See the provider diligence guide for engagement questions to raise early.

Frequently asked questions

Does a sponsorship disclosure qualify a report for the EU label?

Qualification depends on how the research was produced, paid for, labeled, and disseminated under the code. The investment firm also needs sufficient information to assess compliance when it distributes the report under that label.

Does the code prescribe a minimum research fee?

Clause 5 sets a minimum proportion of annual remuneration to be paid at specified points and regulates the compensation structure. The parties negotiate the amount subject to the applicable requirements.

Can management fact-check a draft?

Clause 3 imposes a specific restriction where a draft includes a recommendation or target price. Review procedures also have to protect objectivity and comply with other applicable rules. Establish the process with the relevant compliance team before any draft is shared.